Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma

Bone Marrow Transplant. 2004 May;33(9):921-3. doi: 10.1038/sj.bmt.1704467.

Abstract

Rituximab, an anti-CD20 monoclonal antibody, is increasingly used in the treatment of B-cell non-Hodgkin's lymphoma. Late-onset neutropenia in relation to rituximab has been recently described. In this report, we present six cases occurring after stem cell transplantation and discuss the potential impact of this complication.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20 / chemistry*
  • Antineoplastic Agents / pharmacology*
  • Female
  • Granulocyte Colony-Stimulating Factor / metabolism
  • Humans
  • Lymphoma, Non-Hodgkin / therapy*
  • Male
  • Middle Aged
  • Neutropenia / etiology*
  • Neutrophils / metabolism
  • Rituximab
  • Stem Cell Transplantation
  • Time Factors

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Antineoplastic Agents
  • Granulocyte Colony-Stimulating Factor
  • Rituximab